Clinical Trials Browser

INDUSTRY × Recurrence × Dexamethasone × Clear all

Multiple Myeloma, Recurrence

Multiple Myeloma, Recurrence

Multiple Myeloma, Recurrence

Multiple Myeloma, Recurrence

Lymphoma, Non-Hodgkin, Multiple Myeloma, Recurrence

Multiple Myeloma, Recurrence

Multiple Myeloma, Recurrence

Multiple Myeloma, Recurrence

Multiple Myeloma, Recurrence

Multiple Myeloma, Recurrence

Multiple Myeloma, Recurrence

Recurrence, Lymphoma, Large B-Cell, Diffuse

Multiple Myeloma, Recurrence

Multiple Myeloma, Recurrence

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

Multiple Myeloma, Recurrence

Multiple Myeloma, Neoplasms, Recurrence

Multiple Myeloma, Recurrence

Multiple Myeloma, Recurrence

Multiple Myeloma, Recurrence

Multiple Myeloma, Recurrence

Multiple Myeloma, Recurrence, Bone Marrow Neoplasms

Multiple Myeloma, Recurrence

Multiple Myeloma, Recurrence

Disease, Hematologic Diseases, Multiple Myeloma, Neoplasms, Recurrence

Multiple Myeloma, Recurrence

Multiple Myeloma, Recurrence

Multiple Myeloma, Recurrence

Multiple Myeloma, Neoplasms, Recurrence

Multiple Myeloma, Recurrence

Multiple Myeloma, Recurrence

Multiple Myeloma, Recurrence

Multiple Myeloma, Recurrence

Multiple Myeloma, Recurrence

Multiple Myeloma, Recurrence

Multiple Myeloma, Recurrence

Multiple Myeloma, Recurrence

Multiple Myeloma, Recurrence

Multiple Myeloma, Neoplasms, Recurrence

Multiple Myeloma, Recurrence

Multiple Myeloma, Recurrence

Multiple Myeloma, Recurrence

Multiple Myeloma, Recurrence

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

Disease, Multiple Myeloma, Recurrence, Disease Progression

Multiple Myeloma, Recurrence

Multiple Myeloma, Recurrence

Multiple Myeloma, Recurrence

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

Clinical Trials

A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)

MonumenTAL-3

MajesTEC-9

SUCCESSOR-2

Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma

SUCCESSOR-1

A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma

Daratumumab in Combination With Lenalidomide and Dexamethasone in Relapsed and Relapsed-refractory Multiple Myeloma

A Study Comparing QLS32015 Monotherapy Versus Pomalidomide, Dexamethasone (Pd) or Selinexor, Dexamethasone (Sd) in Participants With Relapsed or Refractory Multiple Myeloma

A Safety, PK and Efficacy Study of CC-92480 Monotherapy and in Combination With Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)

STOMP

A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Phase II Study of QLS32015 Combination Therapy in the Treatment of Multiple Myeloma

SELECT

Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM)

A Study to Evaluate the Safety of Empliciti® (Elotuzumab) When Treating Patients With Multiple Myeloma in Taiwan

A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.

A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)

INTREPID-1

A Study to Determine Dose and Regimen of Durvalumab as Monotherapy or in Combination With Pomalidomide With or Without Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma

BOSTON

ARROW2

PANORAMA_3

ALUMMINATE

A Study of ANV419 Alone or in Combination With Approved Treatments in Patients With Multiple Myeloma (OMNIA-2)

Study of LM-305 in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) and Other Plasma Cell Diseases

Weekly 70 mg/m2 Carfilzomib for Multiple Myeloma Patients Refractory to 27 mg/m2 Carfilzomib

Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma Patients

Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Lemzoparlimab With or Without Oral/IV Dexamethasone and in Combination With Oral/IV/Subcutaneous Anti-Myeloma Regimens in Adult Participants With Multiple Myeloma

A Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-079 Administered Subcutaneously as a Single Agent in Participants With Relapsed/Refractory (r/r) Multiple Myeloma (MM)

FUSIONMM-003

SLAM

KarMMa-3

Carfilzomib in Combination With Dexamethasone (Kd) in Chinese Patients With Relapsed & Refractory Multiple Myeloma

Study of ACY-1215 in Combination With Lenalidomide, and Dexamethasone in Multiple Myeloma

A Study of the Efficacy and Safety of Pomalidomide Capsules Combined With Low-Dose Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma

Mitoxantrone Hydrochloride Liposome Injection, Bortezomib and Dexamethasone in the Treatment of R/R MM

STRATUS

A Study of Venetoclax in Combination With Pomalidomide and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma

MK-0683-095

A Study of Carfilzomib Plus Dexamethasone in Adults With Relapsed or Refractory Multiple Myeloma at US Community Oncology Centers

A Phase I-Ib/II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 Alone and in Combination With Bortezomib, With or Without Dexamethasone, in Patients With Relapsed or Refractory Multiple Myeloma.

MK-0683-074

Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide, Bortezomib and Low-Dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

PANORAMA-1

Phase 1b Study Evaluating ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Dexamethasone in Relapsed or Relapsed-and-Refractory Multiple Myeloma

Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Japanese Patients With Relapsed/Refractory Multiple Myeloma

Open-label Extended Access Program on Lenalidomide Plus Dexamethasone in Chinese Subjects With Relapsed/Refractory Multiple Myeloma Who Participated in CC-5013-MM021 for at Least 1 Year

A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Patients With Relapse or Refractory Multiple Myeloma

NIMBUS